5 Best-performing Canadian Pharma Stocks in 2026

1. BetterLife Pharma (CSE:BETR)

Year-to-date gain: 320 percent
Market cap: C$32.38 million
Share price: C$0.21

BetterLife Pharma is a biopharmaceutical company researching brain health and neural connections (neuroplasticity) to treat severe neurological pain, chronic migraines and cluster headaches. The company outsources manufacturing and lab testing to specialized partners to keep corporate overhead incredibly low.

The company’s primary flagship drug candidate is BETR-001, a non-hallucinogenic LSD derivative. As of mid-July, BetterLife has decided to focus its development on the treatment of migraines and other headache disorders, in part because other therapies using a seratonin-receptor mechanism of action have previously been approved by the US Food and Drug Administration (FDA).

To advance BETR-001’s development, the company appointed Doug Drysdale as executive chairman in May. Drysdale is the former CEO of Cybin, now named Helus Pharma (NASDAQ:HELP), with which he successfully guided a psychedelic molecule from its initial lab design to Phase 3 human clinical trials in just three years.

On June 22, BetterLife secured C$2 million in fresh capital through a convertible debenture to complete the remaining FDA safety studies that would enable BETR-001 to receive Investigational New Drug (IND) status. The money was fully provided by a company insider or director.

Its share price picked up steam in late June and into July as the company engaged firms for GMP manufacturing and its final GLP toxicology study, both of which are required for IND and Phase 1 trials. It plans to file its IND application in the first quarter of 2027.

2. Lobe Sciences (CSE:LOBE)

Year-to-date gain: 80 percent
Market cap: C$25.57 million
Share price: C$0.09

Lobe Sciences is developing prescription medicines to treat rare or difficult illnesses through focused subsidiary companies, including Cynaptec and Applied Lipid Therapeutics.

Of its two core programs, Cynaptec’s L-130, a chemical version of psilocin to treat chronic cluster headaches, remains the main clinical story. Applied Lipid Therapeutics’ program is the S-100 candidate for sickle cell disease.

As per its results for its fiscal Q2 2026 ended February 28, management is advancing development work, spending C$2.12 million on its core programs across its first two fiscal quarters.

The company’s value proposition is tied to pipeline progress and a stronger balance sheet rather than near-term revenue. At the close of its reporting period, the company held about C$4.96 million in combined cash and short-term investments, providing room to fund ongoing clinical trials on budget.

3. Medexus Pharmaceuticals (TSX:MDP)

Year-to-date gain: 74.39 percent
Market cap: C$161.47 million
Share price: C$5.04

Medexus Pharmaceuticals is a specialty pharmaceutical company that acquires, develops and commercializes niche and rare disease drugs in North America.

The company has honed in on hematology, oncology, rheumatology, autoimmune disease, allergies and dermatology. It focuses on bringing in late‑stage or already marketed products via licensing/partnerships and then handling regulatory approval and commercialization in Canada and the US.

GRAFAPEX, which launched commercially in the US in February 2025, is one of the most important branded products in the company’s portfolio. A conditioning regimen, it is used with fludarabine before allogeneic hematopoietic stem cell transplant in patients with acute myeloid leukemia and myelodysplastic syndromes.

In late June, Medexus delivered its results for its 2026 fiscal year ended March 31, reporting net revenue of US$99.3 million, including US$11.6 million from GRAFAPEX. The company anticipates that within five years, the treatment achieve annual net revenue of above US$100 million.

The company highlighted new strategic opportunities in the release, including it securing the rights to commercialize the cell therapy UM171 in Canada, which is in advanced clinical development. This deal adds a longer-term pipeline angle beyond Medexus’ core commercial business.

4. Satellos Bioscience (TSX:MSCL)

Year-to-date gain: 70.96 percent
Market cap: C$285.18 million
Share price: C$13.95

Satellos Bioscience is a Canadian pharmaceutical company expanding treatment options for muscle disorders.

The company is focused specifically on Duchenne muscular dystrophy, developing therapies that target the specific biological pathways involved in regenerating and repairing muscle tissue. Its lead candidate, SAT-3247, targets a protein called AAK1, which regulates the activity of stem cells that activate and differentiate new muscle fibers.

In June, the FDA granted SAT-3247 fast track designation for the treatment of Duchenne, adding to its prior orphan drug and rare pediatric disease designations.

TRAILHEAD is Satellos’ open-label Phase 2 follow-up study in adults with Duchenne, designed to see whether SAT-3247’s early strength gains and biomarker improvements hold up over the long term. The company is also performing a Phase 2 trial of the treatment in pediatric patients named BASECAMP.

An interim readout of TRAILHEAD data published on July 8 showed that the first patients to complete the study, adult males with Duchenne taking SAT-3247, had reduced muscle fat, stable or improved strength and lower creatine kinase concentrations, which suggests the drug may be producing real biological and functional benefit. The patients did not experience serious adverse events.

5. Revive Therapeutics (CSE:RVV)

Year-to-date gain: 66.67 percent
Market cap: C$10.46 million
Share price: C$0.03

Revive Therapeutics focuses on developing treatments for infectious diseases and rare disorders, repurposing existing drugs and pursuing regulatory pathways like orphan drug and fast-track designations.

Its main programs include bucillamine, a rheumatoid arthritis treatment it is exploring for public health emergencies and rare inflammatory disorders. Its latest investor deck says bucillamine has already completed a Phase 3 study for COVID-19 and has received FDA designations for two other programs. In March, it received a patent in Canada for the use of bucillamine in infection diseases such as influenza and COVID-19.

In May, Revive said it has broadened bucillamine beyond infectious disease into defence and biothreat uses, including treatment for nerve agent exposure and chemical threats, as well as pandemic preparedness and medical countermeasures. The company has an ongoing study in collaboration with Defence R&D Canada for nerve agent exposure, and is planning further preclinical work to study the treatment for these indications.

In July, it closed its first tranche of a private placement for gross proceeds of C$246,920.

Revive also has a cannabinoid pharmaceutical portfolio, with FDA orphan drug designations for conditions like autoimmune hepatitis and ischemia-reperfusion injury, and is developing psilocybin-based therapeutics through its Psilocin Pharma subsidiary.